fulzerasib

DRUG2 trials

Sponsors

Zhejiang Genfleet Therapeutics Co. Ltd., Jianxing He

Conditions

KRAS G12C MutationNeoadjuvant TherapyPreviously Untreated Advanced NSCLC Harboring KRAS G12C MutationResectable NSCLCStage IB-IIIA NSCLC

Phase 1

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

CompletedCTIS2022-501451-87-00

Zhejiang Genfleet Therapeutics Co. Ltd.Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Start: 2023-03-31End: 2025-04-29Target: 32Updated: 2025-04-11

Phase 2

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

RecruitingNCT07492342

Jianxing HeKRAS G12C Mutation, Neoadjuvant Therapy, Resectable NSCLC +1

Start: 2026-01-29End: 2027-12-31Target: 30Updated: 2026-03-25